Details of the Drug

General Information of Drug (ID: DMBGZI3)

Drug Name

Chlorpromazine

Synonyms

Aminasine; Aminazin; Aminazine; Ampliactil; Amplicitil; Amplictil; BC 135; Chlor-PZ; Chlor-Promanyl; Chlordelazine; Chlorderazin; Chloropromazine; Chlorpromados; Chlorpromanyl (discontinued); Chlorpromazin; Chlorpromazine (USP/INN); Chlorpromazine Tannate; Chlorpromazine [USAN:INN:BAN]; Chlorpromazinum; Chlorpromazinum [INN-Latin]; Clorpromazina; Clorpromazina [INN-Spanish]; Clorpromazina [Italian]; Contomin; Cromedazine; Elmarin; Esmind; Fenactil; Fenaktyl; Fraction AB; HL 5746; JHICC02042; Largactil; Largactil (TN); Largactil Liquid; Largactil Oral Drops; Largactilothiazine; Largactyl; Megaphen; Novo-Chlorpromazine; Novomazina; Phenactyl; Phenathyl; Phenothiazine hydrochloride; Plegomasine; Plegomazin; Prazilpromactil; Proma; Promactil; Promazil; Propaphen; Propaphenin; Prozil; Psychozine; SKF 2601-A; SKF 2601A; SKF-2601; Sanopron; Thorazine; Thorazine (TN); Thorazine Spansule; Thorazine Suppositories; Thorazine hydrochloride; Torazina; Wintermin; Z80

Indication

Disease Entry	ICD 11	Status	REF
Acute intermittent hepatic porphyria	5C58.11	Approved	[1]
Disruptive behavior disorder	N.A.	Approved	[1]
Psychotic disorder	6A20-6A25	Approved	[1]
Schizophrenia	6A20	Approved	[2]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 3	[3]
Middle East Respiratory Syndrome (MERS)	1D64	Investigative	[4]
Severe acute respiratory syndrome (SARS)	1D65	Investigative	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Antipsychotic Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

318.9

Logarithm of the Partition Coefficient (xlogp)

5.2

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [5]
Clearance: The drug present in the plasma can be removed from the body at the rate of 16 mL/min/kg [6]
Elimination: 0.5% of drug is excreted from urine in the unchanged form [5]
Half-life: The concentration or amount of drug in body reduced by one-half in 11 hours [6]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 52.37222 micromolar/kg/day [7]
Unbound Fraction: The unbound fraction of drug in plasma is 0.056% [6]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 10 L/kg [6]
Water Solubility: The ability of drug to dissolve in water is measured as 400 mg/mL [5]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Adverse drug reaction	Not Available	CHRM1	OT8601UY	[8]
Hepatotoxicity	Not Available	LDHA	OTN7K4XB	[8]
Metabolic disorder	Not Available	AMD1	OTKAGZY3	[8]
Metabolic disorder	Not Available	ODC1	OTNDAGRR	[8]
Parkinsonism	Not Available	MT-ND1	OTCLGIXV	[8]
Tardive dyskinesia	Not Available	DRD3	OT0OFFKB	[8]
Tardive dyskinesia	Not Available	DRD4	OTAJTO7N	[8]
-----------


⏷ Show the Full List of 7 ADR Information of This Drug

Chemical Identifiers

Formula: C17H19ClN2S
IUPAC Name: 3-(2-chlorophenothiazin-10-yl)-N,N-dimethylpropan-1-amine
Canonical SMILES: CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl
InChI: InChI=1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3
InChIKey: ZPEIMTDSQAKGNT-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 2726
ChEBI ID: CHEBI:3647
CAS Number: 34468-21-8
DrugBank ID: DB00477
TTD ID: D01ZII
VARIDT ID: DR00502
INTEDE ID: DR0308
ACDINA ID: D00124

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Antagonist	[9]
HUMAN clathrin-mediated endocytosis (RME)	TTAIY2U	.	Inhibitor	[4]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[10]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[11]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[12]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[13]
Docosahexaenoic acid omega-hydroxylase (CYP4F11)	DEIZLTN	CP4FB_HUMAN	Substrate	[14]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)	OTRT3F3U	HMDH_HUMAN	Gene/Protein Processing	[15]
Acetylcholinesterase (ACHE)	OT2H8HG6	ACES_HUMAN	Gene/Protein Processing	[16]
Acid ceramidase (ASAH1)	OT1DNGXL	ASAH1_HUMAN	Gene/Protein Processing	[17]
Alpha-1-acid glycoprotein 1 (ORM1)	OTZKSBRE	A1AG1_HUMAN	Protein Interaction/Cellular Processes	[18]
Alpha-1-acid glycoprotein 2 (ORM2)	OTRJGZP8	A1AG2_HUMAN	Protein Interaction/Cellular Processes	[18]
Alpha-1-antichymotrypsin (SERPINA3)	OT9BP2S0	AACT_HUMAN	Gene/Protein Processing	[19]
Alpha-fetoprotein (AFP)	OT9GG3ZI	FETA_HUMAN	Gene/Protein Processing	[20]
Amphiregulin (AREG)	OTJFOR67	AREG_HUMAN	Gene/Protein Processing	[20]
Angiotensin-converting enzyme 2 (ACE2)	OTTRZGU7	ACE2_HUMAN	Gene/Protein Processing	[21]
AP-1 complex subunit sigma-1A (AP1S1)	OTQ2H8DN	AP1S1_HUMAN	Gene/Protein Processing	[17]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification

06 Mental, behavioural or neurodevelopmental disorder

Disease Class

ICD-11: 6A20 Schizophrenia

The Studied Tissue

Pre-frontal cortex

The Studied Disease

Schizophrenia [ICD-11:6A20]

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Dopamine D2 receptor (D2R)	DTT	DRD2	9.39E-01	-0.01	-0.05
Dopamine D2 receptor (D2R)	DTT	DRD2	9.91E-01	-0.02	-0.28
P-glycoprotein 1 (ABCB1)	DTP	P-GP	1.19E-01	-1.32E-01	-2.77E-01
P-glycoprotein 1 (ABCB1)	DTP	P-GP	1.65E-01	-1.47E-01	-4.48E-01
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	6.73E-02	6.49E-02	3.07E-01
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	6.45E-01	2.07E-02	1.74E-01
Docosahexaenoic acid omega-hydroxylase (CYP4F11)	DME	CYP4F11	8.22E-01	3.93E-02	1.31E-01
Docosahexaenoic acid omega-hydroxylase (CYP4F11)	DME	CYP4F11	9.82E-01	6.23E-02	2.83E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	2.59E-01	6.29E-02	3.14E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	4.84E-01	-8.38E-02	-8.46E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	4.66E-01	4.25E-02	1.20E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	4.75E-01	5.15E-02	3.64E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Chlorpromazine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Quetiapine	DM1N62C	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Quetiapine.	Schizophrenia [6A20]	[22]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Mesoridazine.	Schizophrenia [6A20]	[22]
Thioridazine	DM35M8J	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Thioridazine.	Schizophrenia [6A20]	[23]
Aripiprazole	DM3NUMH	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Aripiprazole.	Schizophrenia [6A20]	[24]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Iloperidone.	Schizophrenia [6A20]	[22]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Paliperidone.	Schizophrenia [6A20]	[22]
Haloperidol	DM96SE0	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Haloperidol.	Schizophrenia [6A20]	[22]
Perphenazine	DMA4MRX	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Perphenazine.	Schizophrenia [6A20]	[24]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Molindone.	Schizophrenia [6A20]	[24]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Thiothixene.	Schizophrenia [6A20]	[24]
Trifluoperazine	DMKBYWI	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Trifluoperazine.	Schizophrenia [6A20]	[24]
Risperidone	DMN6DXL	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Risperidone.	Schizophrenia [6A20]	[24]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Amisulpride.	Schizophrenia [6A20]	[25]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Asenapine.	Schizophrenia [6A20]	[22]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Pimozide.	Schizophrenia [6A20]	[26]
-----------


⏷ Show the Full List of 15 DDI Information of This Drug

Coadministration of a Drug Treating the Disease Different from Chlorpromazine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Ivosidenib.	Acute myeloid leukaemia [2A60]	[27]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Midostaurin.	Acute myeloid leukaemia [2A60]	[22]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Idarubicin.	Acute myeloid leukaemia [2A60]	[22]
Daunorubicin	DMQUSBT	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Daunorubicin.	Acute myeloid leukaemia [2A60]	[22]
Arn-509	DMT81LZ	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Arn-509.	Acute myeloid leukaemia [2A60]	[26]
Gilteritinib	DMTI0ZO	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Gilteritinib.	Acute myeloid leukaemia [2A60]	[28]
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Chlorpromazine and Oliceridine.	Acute pain [MG31]	[29]
Scopolamine	DMOM8AL	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Scopolamine.	Addictive disorder [6C50-6C5Z]	[24]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[30]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[30]
Tripelennamine	DMZBU15	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Tripelennamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[24]
Memantine	DMD9WSC	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Memantine.	Alzheimer disease [8A20]	[24]
Galantamine	DMEO794	Moderate	Antagonize the effect of Chlorpromazine when combined with Galantamine.	Alzheimer disease [8A20]	[31]
Rivastigmine	DMG629M	Moderate	Antagonize the effect of Chlorpromazine when combined with Rivastigmine.	Alzheimer disease [8A20]	[31]
Donepezil	DMIYG7Z	Moderate	Antagonize the effect of Chlorpromazine when combined with Donepezil.	Alzheimer disease [8A20]	[31]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Chlorpromazine and Metronidazole.	Amoebiasis [1A36]	[32]
Isosorbide dinitrate	DMBI4JG	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Isosorbide dinitrate.	Anal fissure/fistula [DB50]	[33]
Trimethaphan	DMHF4IQ	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Trimethaphan.	Aneurysm/dissection [BD50]	[34]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Ivabradine.	Angina pectoris [BA40]	[26]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Bepridil.	Angina pectoris [BA40]	[22]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Dronedarone.	Angina pectoris [BA40]	[22]
Amyl nitrite	DMJKO05	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Amyl nitrite.	Angina pectoris [BA40]	[33]
Nifedipine	DMSVOZT	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Nifedipine.	Angina pectoris [BA40]	[33]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[35]
Hydroxyzine	DMF8Y74	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Hydroxyzine.	Anxiety disorder [6B00-6B0Z]	[24]
Cilostazol	DMZMSCT	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Cilostazol.	Arterial occlusive disease [BD40]	[22]
Voriconazole	DMAOL2S	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Voriconazole.	Aspergillosis [1F20]	[22]
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Posaconazole.	Aspergillosis [1F20]	[22]
Levalbuterol	DM5YBO1	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Levalbuterol.	Asthma [CA23]	[36]
Terbutaline	DMD4381	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Terbutaline.	Asthma [CA23]	[37]
Pirbuterol	DMI5678	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Pirbuterol.	Asthma [CA23]	[37]
Ephedrine	DMMV0KW	Moderate	Antagonize the effect of Chlorpromazine when combined with Ephedrine.	Asthma [CA23]	[38]
Salbutamol	DMN9CWF	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Salbutamol.	Asthma [CA23]	[36]
Formoterol	DMSOURV	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Formoterol.	Asthma [CA23]	[37]
Lisdexamfetamine	DM6W8V5	Moderate	Antagonize the effect of Chlorpromazine when combined with Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[38]
Desipramine	DMT2FDC	Moderate	Increased plasma concentrations of Chlorpromazine and Desipramine due to competitive inhibition of the same metabolic pathway.	Attention deficit hyperactivity disorder [6A05]	[39]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[40]
Ciprofloxacin XR	DM2NLS9	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[22]
Clarithromycin	DM4M1SG	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[22]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Chlorpromazine and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[22]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[40]
Linezolid	DMGFPU2	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Linezolid.	Bacterial infection [1A00-1C4Z]	[41]
Gemifloxacin	DMHT34O	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[40]
Norfloxacin	DMIZ6W2	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[40]
Levofloxacin	DMS60RB	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[40]
Lomefloxacin	DMVRH9C	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[22]
Telithromycin	DMZ4P3A	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Telithromycin.	Bacterial infection [1A00-1C4Z]	[22]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Retigabine.	Behcet disease [4A62]	[22]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Cariprazine.	Bipolar disorder [6A60]	[24]
Loperamide	DMOJZQ9	Moderate	Additive antimotility effects by the combination of Chlorpromazine and Loperamide.	Bowel habit change [ME05]	[42]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Eribulin.	Breast cancer [2C60-2C6Y]	[22]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Lapatinib.	Breast cancer [2C60-2C6Y]	[22]
Tamoxifen	DMLB0EZ	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Tamoxifen.	Breast cancer [2C60-2C6Y]	[22]
Toremifene	DMQYUWG	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Toremifene.	Breast cancer [2C60-2C6Y]	[22]
Sotalol	DML60TN	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Sotalol.	Cardiac arrhythmia [BC9Z]	[22]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[43]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[44]
Olodaterol	DM62B78	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[37]
Vilanterol	DMF5EK1	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[36]
Tiotropium	DMFDC0Q	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Tiotropium.	Chronic obstructive pulmonary disease [CA22]	[44]
Salmeterol	DMIEU69	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[37]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[44]
Indacaterol	DMQJHR7	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[37]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[37]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Chlorpromazine and Dihydrocodeine.	Chronic pain [MG30]	[45]
Oxaliplatin	DMQNWRD	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Oxaliplatin.	Colorectal cancer [2B91]	[22]
Isoproterenol	DMK7MEY	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Isoproterenol.	Conduction disorder [BC63]	[36]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Halothane.	Corneal disease [9A76-9A78]	[22]
Propofol	DMB4OLE	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Propofol.	Corneal disease [9A76-9A78]	[46]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Sevoflurane.	Corneal disease [9A76-9A78]	[22]
Alfentanil	DMVO0UB	Major	Additive CNS depression effects by the combination of Chlorpromazine and Alfentanil.	Corneal disease [9A76-9A78]	[29]
Remifentanil	DMZTXCH	Major	Additive CNS depression effects by the combination of Chlorpromazine and Remifentanil.	Corneal disease [9A76-9A78]	[29]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Probucol.	Coronary atherosclerosis [BA80]	[22]
Dextromethorphan	DMUDJZM	Moderate	Decreased metabolism of Chlorpromazine caused by Dextromethorphan mediated inhibition of CYP450 enzyme.	Cough [MD12]	[32]
Clofazimine	DMEBOFW	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Clofazimine.	Crohn disease [DD70]	[47]
Mifepristone	DMGZQEF	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Mifepristone.	Cushing syndrome [5A70]	[22]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Pasireotide.	Cushing syndrome [5A70]	[22]
Osilodrostat	DMIJC9X	Moderate	Decreased metabolism of Chlorpromazine caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[32]
Cyclandelate	DMO0R76	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Cyclandelate.	Dementia [6D80-6D8Z]	[33]
Sertraline	DM0FB1J	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Sertraline.	Depression [6A70-6A7Z]	[22]
Trimipramine	DM1SC8M	Moderate	Increased plasma concentrations of Chlorpromazine and Trimipramine due to competitive inhibition of the same metabolic pathway.	Depression [6A70-6A7Z]	[39]
Cyclobenzaprine	DM1YBRM	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Cyclobenzaprine.	Depression [6A70-6A7Z]	[24]
Nortriptyline	DM4KDYJ	Moderate	Increased plasma concentrations of Chlorpromazine and Nortriptyline due to competitive inhibition of the same metabolic pathway.	Depression [6A70-6A7Z]	[39]
Paroxetine	DM5PVQE	Moderate	Decreased metabolism of Chlorpromazine caused by Paroxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[48]
Selegiline	DM6034S	Moderate	Additive CNS depression effects by the combination of Chlorpromazine and Selegiline.	Depression [6A70-6A7Z]	[41]
Isocarboxazid	DMAF1NB	Moderate	Additive CNS depression effects by the combination of Chlorpromazine and Isocarboxazid.	Depression [6A70-6A7Z]	[41]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Escitalopram.	Depression [6A70-6A7Z]	[22]
Tranylcypromine	DMGB5RE	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Tranylcypromine.	Depression [6A70-6A7Z]	[41]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and OPC-34712.	Depression [6A70-6A7Z]	[24]
Phenelzine	DMHIDUE	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Phenelzine.	Depression [6A70-6A7Z]	[41]
Clomipramine	DMINRKW	Moderate	Increased plasma concentrations of Chlorpromazine and Clomipramine due to competitive inhibition of the same metabolic pathway.	Depression [6A70-6A7Z]	[39]
Trazodone	DMK1GBJ	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Trazodone.	Depression [6A70-6A7Z]	[49]
Amoxapine	DMKITQE	Moderate	Increased plasma concentrations of Chlorpromazine and Amoxapine due to competitive inhibition of the same metabolic pathway.	Depression [6A70-6A7Z]	[39]
Doxepin	DMPI98T	Moderate	Increased plasma concentrations of Chlorpromazine and Doxepin due to competitive inhibition of the same metabolic pathway.	Depression [6A70-6A7Z]	[39]
Maprotiline	DMPWB7T	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Maprotiline.	Depression [6A70-6A7Z]	[24]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Chlorpromazine and Esketamine.	Depression [6A70-6A7Z]	[32]
Nitroglycerin	DMQ2491	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Nitroglycerin.	Diabetic foot ulcer [BD54]	[33]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Mepenzolate.	Digestive system disease [DE2Z]	[24]
Tetrabenazine	DMYWQ0O	Major	Additive antidopaminergic effects by the combination of Chlorpromazine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[50]
Meclizine	DMS7T13	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Meclizine.	Dizziness and giddiness [MB48]	[24]
Deutetrabenazine	DMUPFLI	Major	Additive antidopaminergic effects by the combination of Chlorpromazine and Deutetrabenazine.	Dystonic disorder [8A02]	[51]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Ingrezza.	Dystonic disorder [8A02]	[52]
Zonisamide	DM0DTF7	Major	Additive CNS depression effects by the combination of Chlorpromazine and Zonisamide.	Epilepsy/seizure [8A61-8A6Z]	[53]
Diphenhydramine	DMKQTBA	Moderate	Antagonize the effect of Chlorpromazine when combined with Diphenhydramine.	Episodic vestibular syndrome [AB31]	[54]
Guanabenz	DM5QWEL	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Guanabenz.	Essential hypertension [BA00]	[33]
Ethacrynic acid	DM60QMR	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Ethacrynic acid.	Essential hypertension [BA00]	[34]
Phenoxybenzamine	DM8KSQH	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Phenoxybenzamine.	Essential hypertension [BA00]	[33]
Nicardipine	DMCDYW7	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Nicardipine.	Essential hypertension [BA00]	[33]
Mecamylamine	DMGQFYB	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Mecamylamine.	Essential hypertension [BA00]	[33]
Benzthiazide	DMQWZ0H	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Benzthiazide.	Essential hypertension [BA00]	[32]
Nadolol	DMW6GVL	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Nadolol.	Essential hypertension [BA00]	[33]
Mirabegron	DMS1GYT	Moderate	Decreased metabolism of Chlorpromazine caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[55]
Tolterodine	DMSHPW8	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Tolterodine.	Functional bladder disorder [GC50]	[24]
Darifenacin	DMWXLYZ	Moderate	Decreased metabolism of Chlorpromazine caused by Darifenacin mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[56]
Pentamidine	DMHZJCG	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Pentamidine.	Fungal infection [1F29-1F2F]	[22]
Terbinafine	DMI6HUW	Moderate	Decreased metabolism of Chlorpromazine caused by Terbinafine mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[57]
Ketoconazole	DMPZI3Q	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Ketoconazole.	Fungal infection [1F29-1F2F]	[22]
Amphotericin B	DMTAJQE	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Amphotericin B.	Fungal infection [1F29-1F2F]	[32]
Phentolamine	DMXYJOB	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Phentolamine.	Gangrene [MC85]	[33]
Propantheline	DM2EN6G	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Propantheline.	Gastric ulcer [DA60]	[24]
Cisapride	DMY7PED	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Cisapride.	Gastro-oesophageal reflux disease [DA22]	[22]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[22]
Acetazolamide	DM1AF5U	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Acetazolamide.	Glaucoma [9C61]	[32]
Isoflurophate	DMBSK7X	Moderate	Antagonize the effect of Chlorpromazine when combined with Isoflurophate.	Glaucoma [9C61]	[58]
Carteolol	DMFMDOB	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Carteolol.	Glaucoma [9C61]	[33]
Brimonidine	DMQLT4N	Moderate	Additive CNS depression effects by the combination of Chlorpromazine and Brimonidine.	Glaucoma [9C61]	[59]
Pilocarpine	DMV9ADG	Moderate	Antagonize the effect of Chlorpromazine when combined with Pilocarpine.	Glaucoma [9C61]	[58]
Eplerenone	DMF0NQR	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Eplerenone.	Heart failure [BD10-BD1Z]	[33]
Carvedilol	DMHTEAO	Moderate	Increased plasma concentrations of Chlorpromazine and Carvedilol due to competitive inhibition of the same metabolic pathway.	Heart failure [BD10-BD1Z]	[60]
Chlorothiazide	DMLHESP	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Chlorothiazide.	Heart failure [BD10-BD1Z]	[32]
Furosemide	DMMQ8ZG	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Furosemide.	Heart failure [BD10-BD1Z]	[32]
Amiloride	DMRTSGP	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Amiloride.	Heart failure [BD10-BD1Z]	[33]
Bumetanide	DMRV7H0	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Bumetanide.	Heart failure [BD10-BD1Z]	[32]
Hydroflumethiazide	DMVPUQI	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[32]
Procarbazine	DMIK367	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Procarbazine.	Hodgkin lymphoma [2B30]	[41]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[61]
Cobicistat	DM6L4H2	Moderate	Decreased clearance of Chlorpromazine due to the transporter inhibition by Cobicistat.	Human immunodeficiency virus disease [1C60-1C62]	[62]
Efavirenz	DMC0GSJ	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[63]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[64]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[22]
Abacavir	DMMN36E	Minor	Increased plasma concentrations of Chlorpromazine and Abacavir due to competitive inhibition of the same metabolic pathway.	Human immunodeficiency virus disease [1C60-1C62]	[65]
Ritonavir	DMU764S	Moderate	Decreased metabolism of Chlorpromazine caused by Ritonavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[66]
Isosorbide mononitrate	DMYLMU0	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Isosorbide mononitrate.	Hydrocephalus [8D64]	[33]
Cinacalcet	DMCX0K3	Moderate	Decreased metabolism of Chlorpromazine caused by Cinacalcet mediated inhibition of CYP450 enzyme.	Hyper-parathyroidism [5A51]	[32]
Eprosartan	DM07K2I	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Eprosartan.	Hypertension [BA00-BA04]	[33]
Acebutolol	DM0TI4U	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Acebutolol.	Hypertension [BA00-BA04]	[33]
Moexipril	DM26E4B	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Moexipril.	Hypertension [BA00-BA04]	[33]
Bisoprolol	DM3UZ95	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Bisoprolol.	Hypertension [BA00-BA04]	[33]
Captopril	DM458UM	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Captopril.	Hypertension [BA00-BA04]	[33]
Penbutolol	DM4ES8F	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Penbutolol.	Hypertension [BA00-BA04]	[33]
Trandolapril	DM4L6EU	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Trandolapril.	Hypertension [BA00-BA04]	[33]
Methyldopa	DM5I621	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Methyldopa.	Hypertension [BA00-BA04]	[33]
Losartan	DM72JXH	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Losartan.	Hypertension [BA00-BA04]	[33]
Nebivolol	DM7F1PA	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Nebivolol.	Hypertension [BA00-BA04]	[33]
Fosinopril	DM9NJ52	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Fosinopril.	Hypertension [BA00-BA04]	[33]
Doxazosin	DM9PLRH	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Doxazosin.	Hypertension [BA00-BA04]	[33]
TAK-491	DMCF6SX	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and TAK-491.	Hypertension [BA00-BA04]	[33]
Pindolol	DMD2NV7	Moderate	Increased plasma concentrations of Chlorpromazine and Pindolol due to competitive inhibition of the same metabolic pathway.	Hypertension [BA00-BA04]	[60]
Fenoldopam	DMFAOKP	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Fenoldopam.	Hypertension [BA00-BA04]	[33]
Indapamide	DMGN1PW	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Indapamide.	Hypertension [BA00-BA04]	[32]
Benazepril	DMH1M9B	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Benazepril.	Hypertension [BA00-BA04]	[33]
Trichlormethiazide	DMHAQCO	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Trichlormethiazide.	Hypertension [BA00-BA04]	[33]
Labetalol	DMK8U72	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Labetalol.	Hypertension [BA00-BA04]	[33]
Enalapril	DMNFUZR	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Enalapril.	Hypertension [BA00-BA04]	[33]
Perindopril	DMOPZDT	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Perindopril.	Hypertension [BA00-BA04]	[33]
Felodipine	DMOSW35	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Felodipine.	Hypertension [BA00-BA04]	[33]
Quinapril	DMR8H31	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Quinapril.	Hypertension [BA00-BA04]	[33]
Deserpidine	DMRH7CV	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Deserpidine.	Hypertension [BA00-BA04]	[33]
Telmisartan	DMS3GX2	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Telmisartan.	Hypertension [BA00-BA04]	[33]
Irbesartan	DMTP1DC	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Irbesartan.	Hypertension [BA00-BA04]	[33]
Hydralazine	DMU8JGH	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Hydralazine.	Hypertension [BA00-BA04]	[33]
Lisinopril	DMUOK4C	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Lisinopril.	Hypertension [BA00-BA04]	[33]
Hydrochlorothiazide	DMUSZHD	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Hydrochlorothiazide.	Hypertension [BA00-BA04]	[32]
Clevidipine butyrate	DMW4M97	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Clevidipine butyrate.	Hypertension [BA00-BA04]	[33]
Fludrocortisone	DMUDIR8	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Fludrocortisone.	Hypo-osmolality/hyponatraemia [5C72]	[32]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Chlorpromazine caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[32]
Amantadine	DMS3YE9	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Amantadine.	Influenza [1E30-1E32]	[67]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Chlorpromazine caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[68]
Propiomazine	DMKY8V1	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Propiomazine.	Insomnia [7A00-7A0Z]	[24]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and ITI-007.	Insomnia [7A00-7A0Z]	[24]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[22]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Phenolphthalein.	Irritable bowel syndrome [DD91]	[22]
Clidinium	DMUMQZ0	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Clidinium.	Irritable bowel syndrome [DD91]	[24]
Dicyclomine	DMZSDGX	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Dicyclomine.	Irritable bowel syndrome [DD91]	[24]
Physostigmine	DM2N0TO	Moderate	Antagonize the effect of Chlorpromazine when combined with Physostigmine.	Lips/oral mucosa miscellaneous disorder [DA02]	[31]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Chlorpromazine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[26]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Crizotinib.	Lung cancer [2C25]	[69]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Chlorpromazine and Porfimer Sodium.	Lung cancer [2C25]	[70]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Ceritinib.	Lung cancer [2C25]	[22]
Dacomitinib	DMOH8VY	Moderate	Decreased metabolism of Chlorpromazine caused by Dacomitinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[71]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Osimertinib.	Lung cancer [2C25]	[72]
Capmatinib	DMYCXKL	Moderate	Decreased metabolism of Chlorpromazine caused by Capmatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[32]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Selpercatinib.	Lung cancer [2C25]	[26]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Lumefantrine.	Malaria [1F40-1F45]	[32]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Halofantrine.	Malaria [1F40-1F45]	[73]
Chloroquine	DMSI5CB	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Chloroquine.	Malaria [1F40-1F45]	[74]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Hydroxychloroquine.	Malaria [1F40-1F45]	[74]
Primaquine	DMWQ16I	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Primaquine.	Malaria [1F40-1F45]	[22]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[26]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Chlorpromazine caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[75]
Arsenic trioxide	DM61TA4	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[76]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Vemurafenib.	Melanoma [2C30]	[22]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and LGX818.	Melanoma [2C30]	[77]
Ethinyl estradiol	DMODJ40	Moderate	Decreased clearance of Chlorpromazine due to the transporter inhibition by Ethinyl estradiol.	Menopausal disorder [GA30]	[78]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Chlorpromazine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[79]
Propranolol	DM79NTF	Moderate	Increased plasma concentrations of Chlorpromazine and Propranolol due to competitive inhibition of the same metabolic pathway.	Migraine [8A80]	[60]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Chlorpromazine and Lasmiditan.	Migraine [8A80]	[80]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Chlorpromazine and Flibanserin.	Mood disorder [6A60-6E23]	[81]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Panobinostat.	Multiple myeloma [2A83]	[82]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Chlorpromazine and Thalidomide.	Multiple myeloma [2A83]	[83]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Siponimod.	Multiple sclerosis [8A40]	[32]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Fingolimod.	Multiple sclerosis [8A40]	[22]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Ozanimod.	Multiple sclerosis [8A40]	[84]
Methoxsalen	DME8FZ9	Moderate	Increased risk of photosensitivity reactions by the combination of Chlorpromazine and Methoxsalen.	Mycosis fungoides [2B01]	[32]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Romidepsin.	Mycosis fungoides [2B01]	[22]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Chlorpromazine caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[26]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Nilotinib.	Myeloproliferative neoplasm [2A20]	[22]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Chlorpromazine caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[85]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Dasatinib.	Myeloproliferative neoplasm [2A20]	[86]
Dextroamphetamine	DMMIHVP	Moderate	Antagonize the effect of Chlorpromazine when combined with Dextroamphetamine.	Narcolepsy [7A20]	[38]
Phenindamine	DMDTC7R	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Phenindamine.	Nasopharyngitis [CA00]	[24]
Dimenhydrinate	DM264B3	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Dimenhydrinate.	Nausea/vomiting [MD90]	[24]
Promethazine	DM6I5GR	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Promethazine.	Nausea/vomiting [MD90]	[24]
Rolapitant	DM8XP26	Moderate	Decreased metabolism of Chlorpromazine caused by Rolapitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[87]
Cyclizine	DM9G7BS	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Cyclizine.	Nausea/vomiting [MD90]	[24]
Metoclopramide	DMFA5MY	Major	Additive antidopaminergic effects by the combination of Chlorpromazine and Metoclopramide.	Nausea/vomiting [MD90]	[88]
Granisetron	DMIUW25	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Granisetron.	Nausea/vomiting [MD90]	[22]
Dolasetron	DMMG26Z	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Dolasetron.	Nausea/vomiting [MD90]	[22]
Ondansetron	DMOTQ1I	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Ondansetron.	Nausea/vomiting [MD90]	[22]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Chlorpromazine and Bupropion.	Nicotine use disorder [6C4A]	[22]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Entrectinib.	Non-small cell lung cancer [2C25]	[32]
Phendimetrazine	DM6TS1N	Moderate	Antagonize the effect of Chlorpromazine when combined with Phendimetrazine.	Obesity [5B80-5B81]	[38]
Amfepramone	DM9YSNQ	Moderate	Antagonize the effect of Chlorpromazine when combined with Amfepramone.	Obesity [5B80-5B81]	[38]
Lorcaserin	DMG6OYJ	Moderate	Increased risk of hyperprolactinemic effects by the combination of Chlorpromazine and Lorcaserin.	Obesity [5B80-5B81]	[89]
Benzphetamine	DMIJATC	Moderate	Antagonize the effect of Chlorpromazine when combined with Benzphetamine.	Obesity [5B80-5B81]	[38]
Mazindol	DMZ36RN	Moderate	Antagonize the effect of Chlorpromazine when combined with Mazindol.	Obesity [5B80-5B81]	[38]
Metolazone	DMB39LO	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Metolazone.	Oedema [MG29]	[32]
Polythiazide	DMCH80F	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Polythiazide.	Oedema [MG29]	[32]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Levomethadyl Acetate.	Opioid use disorder [6C43]	[26]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Lofexidine.	Opioid use disorder [6C43]	[22]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Chlorpromazine and Apraclonidine.	Optic nerve disorder [9C40]	[59]
Rofecoxib	DM3P5DA	Moderate	Decreased metabolism of Chlorpromazine caused by Rofecoxib mediated inhibition of CYP450 enzyme.	Osteoarthritis [FA00-FA05]	[32]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Rucaparib.	Ovarian cancer [2C73]	[22]
Pentazocine	DM1XBHS	Major	Additive CNS depression effects by the combination of Chlorpromazine and Pentazocine.	Pain [MG30-MG3Z]	[29]
Dextropropoxyphene	DM23HCX	Major	Additive CNS depression effects by the combination of Chlorpromazine and Dextropropoxyphene.	Pain [MG30-MG3Z]	[90]
Butorphanol	DM5KYPJ	Major	Additive CNS depression effects by the combination of Chlorpromazine and Butorphanol.	Pain [MG30-MG3Z]	[29]
Oxymorphone	DM65AGJ	Major	Additive CNS depression effects by the combination of Chlorpromazine and Oxymorphone.	Pain [MG30-MG3Z]	[29]
Levorphanol	DMGS80V	Major	Additive CNS depression effects by the combination of Chlorpromazine and Levorphanol.	Pain [MG30-MG3Z]	[29]
Dezocine	DMJDB0Y	Major	Additive CNS depression effects by the combination of Chlorpromazine and Dezocine.	Pain [MG30-MG3Z]	[29]
Flavoxate	DMKV4NL	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Flavoxate.	Pain [MG30-MG3Z]	[24]
Nalbuphine	DMOSQGU	Major	Additive CNS depression effects by the combination of Chlorpromazine and Nalbuphine.	Pain [MG30-MG3Z]	[29]
Methamphetamine	DMPM4SK	Moderate	Antagonize the effect of Chlorpromazine when combined with Methamphetamine.	Pain [MG30-MG3Z]	[91]
Buprenorphine	DMPRI8G	Major	Additive CNS depression effects by the combination of Chlorpromazine and Buprenorphine.	Pain [MG30-MG3Z]	[92]
Hydrocodone	DMQ2JO5	Major	Additive CNS depression effects by the combination of Chlorpromazine and Hydrocodone.	Pain [MG30-MG3Z]	[29]
Oxycodone	DMXLKHV	Major	Additive CNS depression effects by the combination of Chlorpromazine and Oxycodone.	Pain [MG30-MG3Z]	[29]
Thiabendazole	DM7YCK3	Moderate	Decreased metabolism of Chlorpromazine caused by Thiabendazole mediated inhibition of CYP450 enzyme.	Parasitic worm infestation [1F90]	[32]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Triclabendazole.	Parasitic worm infestation [1F90]	[22]
Safinamide	DM0YWJC	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Safinamide.	Parkinsonism [8A00]	[41]
Pergolide	DM14MAE	Moderate	Antagonize the effect of Chlorpromazine when combined with Pergolide.	Parkinsonism [8A00]	[93]
Opicapone	DM1BKA6	Moderate	Antagonize the effect of Chlorpromazine when combined with Opicapone.	Parkinsonism [8A00]	[93]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Rasagiline.	Parkinsonism [8A00]	[41]
Biperiden	DME78OA	Moderate	Antagonize the effect of Chlorpromazine when combined with Biperiden.	Parkinsonism [8A00]	[54]
Entacapone	DMLBVKQ	Moderate	Antagonize the effect of Chlorpromazine when combined with Entacapone.	Parkinsonism [8A00]	[93]
Levodopa	DMN3E57	Moderate	Antagonize the effect of Chlorpromazine when combined with Levodopa.	Parkinsonism [8A00]	[93]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Pimavanserin.	Parkinsonism [8A00]	[94]
Orphenadrine	DMW542E	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Orphenadrine.	Parkinsonism [8A00]	[24]
Apomorphine	DMX38HQ	Moderate	Antagonize the effect of Chlorpromazine when combined with Apomorphine.	Parkinsonism [8A00]	[95]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Chlorpromazine caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[96]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Methylscopolamine.	Peptic ulcer [DA61]	[24]
Famotidine	DMRL3AB	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Famotidine.	Peptic ulcer [DA61]	[32]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[97]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Lefamulin.	Pneumonia [CA40]	[98]
Hydrocortisone	DMGEMB7	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Hydrocortisone.	Postoperative inflammation [1A00-CA43]	[32]
Ritodrine	DM4V6RL	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Ritodrine.	Preterm labour/delivery [JB00]	[37]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Degarelix.	Prostate cancer [2C82]	[26]
ABIRATERONE	DM8V75C	Moderate	Decreased metabolism of Chlorpromazine caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[99]
Nilutamide	DMFN07X	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Nilutamide.	Prostate cancer [2C82]	[26]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Enzalutamide.	Prostate cancer [2C82]	[26]
Flutamide	DMK0O7U	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Flutamide.	Prostate cancer [2C82]	[26]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Relugolix.	Prostate cancer [2C82]	[26]
Bicalutamide	DMZMSPF	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Bicalutamide.	Prostate cancer [2C82]	[26]
Terazosin	DM3JCVS	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Terazosin.	Prostate hyperplasia [GA90]	[33]
Tamsulosin	DM5QF9V	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Tamsulosin.	Prostate hyperplasia [GA90]	[33]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Silodosin.	Prostate hyperplasia [GA90]	[33]
Levomepromazine	DMIKFEL	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[24]
Fluphenazine	DMIT8LX	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Fluphenazine.	Psychotic disorder [6A20-6A25]	[24]
Triflupromazine	DMKFQJP	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Triflupromazine.	Psychotic disorder [6A20-6A25]	[24]
Tolazoline	DMI40NL	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Tolazoline.	Pulmonary hypertension [BB01]	[33]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[100]
Neupro	DMHEAB1	Moderate	Antagonize the effect of Chlorpromazine when combined with Neupro.	Restless legs syndrome [7A80]	[93]
Celecoxib	DM6LOQU	Moderate	Decreased metabolism of Chlorpromazine caused by Celecoxib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[101]
Fentanyl	DM8WAHT	Major	Additive CNS depression effects by the combination of Chlorpromazine and Fentanyl.	Sensation disturbance [MB40]	[29]
Sufentanil	DMU7YEL	Major	Additive CNS depression effects by the combination of Chlorpromazine and Sufentanil.	Sensation disturbance [MB40]	[29]
Vardenafil	DMTBGW8	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Vardenafil.	Sexual dysfunction [HA00-HA01]	[22]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[22]
Cisplatin	DMRHGI9	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Cisplatin.	Solid tumour/cancer [2A00-2F9Z]	[32]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[22]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[26]
Doxorubicin	DMVP5YE	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[22]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Pitolisant.	Somnolence [MG42]	[22]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[22]
Adenosine	DMM2NSK	Moderate	Increased risk of ventricular arrhythmias by the combination of Chlorpromazine and Adenosine.	Supraventricular tachyarrhythmia [BC81]	[22]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Chlorpromazine due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[102]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Lenvatinib.	Thyroid cancer [2D10]	[22]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Cabozantinib.	Thyroid cancer [2D10]	[26]
Papaverine	DMCA9QP	Moderate	Additive hypotensive effects by the combination of Chlorpromazine and Papaverine.	Tonus and reflex abnormality [MB47]	[33]
Tizanidine	DMR2IQ4	Moderate	Additive CNS depression effects by the combination of Chlorpromazine and Tizanidine.	Tonus and reflex abnormality [MB47]	[103]
Tacrolimus	DMZ7XNQ	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Tacrolimus.	Transplant rejection [NE84]	[22]
Atropine	DMEN6X7	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Atropine.	Unspecific substance harmful effect [NE6Z]	[24]
Astemizole	DM2HN6Q	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Astemizole.	Vasomotor/allergic rhinitis [CA08]	[22]
Chlorpheniramine	DM5URA2	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Chlorpheniramine.	Vasomotor/allergic rhinitis [CA08]	[24]
Methdilazine	DMAUHQX	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[24]
Carbinoxamine	DMCT31R	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Carbinoxamine.	Vasomotor/allergic rhinitis [CA08]	[24]
Brompheniramine	DMFOVSD	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Brompheniramine.	Vasomotor/allergic rhinitis [CA08]	[24]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[24]
Azatadine	DMZ80SB	Moderate	Additive anticholinergic effects by the combination of Chlorpromazine and Azatadine.	Vasomotor/allergic rhinitis [CA08]	[24]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Procainamide.	Ventricular tachyarrhythmia [BC71]	[22]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Propafenone.	Ventricular tachyarrhythmia [BC71]	[22]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Chlorpromazine and Flecainide.	Ventricular tachyarrhythmia [BC71]	[22]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Chlorpromazine and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[22]
-----------


⏷ Show the Full List of 320 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
D&C red no. 30	E00456	3000709	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
methylparaben	E00149	7456	Antimicrobial preservative
Propyl 4-hydroxybenzoate	E00141	7175	Antimicrobial preservative
Quinoline yellow WS	E00309	24671	Colorant
Sodium benzoate	E00432	517055	Antimicrobial preservative; lubricant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Allyl sucrose	E00604	129637651	Other agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Calcium sulfate anhydrous	E00303	24497	Desiccant; Diluent
Ferrosoferric oxide	E00231	14789	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
--------------------


⏷ Show the Full List of 17 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Chlorpromazine 100 mg tablet	100 mg	Oral Tablet	Oral
Chlorpromazine 25 mg tablet	25 mg	Oral Tablet	Oral
Chlorpromazine 50 mg tablet	50 mg	Oral Tablet	Oral
Chlorpromazine 10 mg tablet	10 mg	Oral Tablet	Oral
Chlorpromazine 200 mg tablet	200 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Chlorpromazine FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 83).
3	ClinicalTrials.gov (NCT04366739) Repurposing of Chlorpromazine in Covid-19 Treatment. U.S. National Institutes of Health.
4	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
5	BDDCS applied to over 900 drugs
6	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
9	Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
10	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
11	Effect of classic and atypical neuroleptics on cytochrome P450 3A (CYP3A) in rat liver. Pharmacol Rep. 2012;64(6):1411-8.
12	Use of antidepressant drugs in schizophrenic patients with depression. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9.
13	Functional polymorphisms of the cytochrome P450 1A2 (CYP1A2) gene and prolonged QTc interval in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Aug 15;31(6):1297-302.
14	Expression and characterization of human cytochrome P450 4F11: putative role in the metabolism of therapeutic drugs and eicosanoids. Toxicol Appl Pharmacol. 2004 Sep 15;199(3):295-304.
15	Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs. BMC Neurosci. 2006 Oct 20;7:69.
16	Interaction of dichlorvos and anticholinesterases on the in vitro inhibition of human blood cholinesterases. Toxicol Appl Pharmacol. 1974 Feb;27(2):456-63.
17	Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol Sci. 2007 Mar;96(1):101-14.
18	Binding of disopyramide, methadone, dipyridamole, chlorpromazine, lignocaine and progesterone to the two main genetic variants of human alpha 1-acid glycoprotein: evidence for drug-binding differences between the variants and for the presence of two separate drug-binding sites on alpha 1-acid glycoprotein. Pharmacogenetics. 1996 Oct;6(5):403-15. doi: 10.1097/00008571-199610000-00004.
19	A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
20	Effects of chlorpromazine with and without UV irradiation on gene expression of HepG2 cells. Mutat Res. 2005 Aug 4;575(1-2):47-60. doi: 10.1016/j.mrfmmm.2005.03.002. Epub 2005 Apr 26.
21	Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
22	Canadian Pharmacists Association.
23	Bluhm RE, Wilkinson GR, Shelton R, Branch RA "Genetically determined drug-metabolizing activity and desipramine- associated cardiotoxicity: a case report." Clin Pharmacol Ther 53 (1993): 89-95. [PMID: 8422746]
24	Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
25	Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
26	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
27	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
28	Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
29	Cerner Multum, Inc. "Canadian Product Information.".
30	Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
31	Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
32	Cerner Multum, Inc. "Australian Product Information.".
33	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
34	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
35	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
36	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
37	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
38	Achor MB, Extein I "Diet aids, mania, and affective illness" Am J Psychiatry 138 (1981): 392. [PMID: 7468847]
39	Bock JL, Nelson JC, Gray S, Jatlow PI "Desipramine hydroxylation: variability and effect of antipsychotic drugs." Clin Pharmacol Ther 33 (1983): 322-8. [PMID: 6130865]
40	Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
41	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
42	Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
43	Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
44	Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
45	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
46	Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
47	Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
48	Nicholson SD "Extra pyramidal side effects associated with paroxetine." West Engl Med J 107 (1992): 90-1. [PMID: 1308691]
49	Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]
50	Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH "Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease." Neurology 31 (1981): 1022-5. [PMID: 6115336]
51	Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
52	Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
53	Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
54	Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA "Anticholinergic psychosis in a patient receiving usual doses of haloperidol." Clin Pharm 2 (1983): 174-8. [PMID: 6883947]
55	Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
56	Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
57	AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
58	Multum Information Services, Inc. Expert Review Panel.
59	Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
60	Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9. [PMID: 7663034]
61	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
62	Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
63	Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
64	Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
65	Product Information. Ziagen (abacavir). Glaxo Wellcome, Research Triangle Pk, NC.
66	Product Information. Norvir (ritonavir). Abbott Pharmaceutical, Abbott Park, IL.
67	Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
68	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
69	Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
70	Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
71	Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
72	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
73	Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
74	Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
75	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
76	Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
77	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
78	Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8. [PMID: 8162660]
79	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
80	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
81	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
82	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
83	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
84	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
85	Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
86	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
87	Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
88	Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985): 930-2. [PMID: 3929968]
89	Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
90	Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
91	Lake CR "Manic psychosis after coffee and phenylpropanolamine." Biol Psychiatry 30 (1991): 401-4. [PMID: 1912131]
92	Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
93	Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
94	Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
95	Product Information. Apokyn (apomorphine). Mylan Pharmaceuticals Inc, Morgantown, WV.
96	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
97	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
98	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
99	Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
100	Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
101	Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
102	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
103	Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.